Compare Davita Inc (DVA) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Oscar Health Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Oscar Health Inc trades at $33.19 (market cap $10.22B). The key difference: Davita Inc and Oscar Health Inc are close in size by market cap, and Oscar Health Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Oscar Health Inc for 15 Days on average.
| DVA | OSCR | |
|---|---|---|
Market Cap | $11.29B | $10.22B |
Volume | 582,204 | 4,123,394 |
Sector | Health | Health |
52-Week High | $240.96 | $33.81 |
52-Week Low | $103.87 | $10.85 |
Typical Hold Time | 113 Days | 15 Days |
Enterprise Value | $24.01B | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
OSCR trades at $32.91, up 1.76% today, with a bullish technical outlook from moving averages and mixed oscillators. The stock shows strong revenue growth, with 2026 revenue projected at $15.3B, and profitability turning positive with a net income margin of 3.59%. Recent news highlights market share gains in the ACA sector and raised 2026 guidance, though Q3 2026 EPS is yet to be reported.
The outlook is positive with analyst consensus at Buy and a $34 price target, but risks include rising medical costs and execution challenges. Upside potential exists from scalable growth and margin expansion, yet volatility near resistance levels and competitive pressures warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
